Researchers say they have discovered that the protein puromycin-sensitive aminopeptidase (NPEPPS) plays a role in regulating response to platinum chemotherapy in patients with bladder cancer ..read more

Researchers have performed the most comprehensive analysis to date of cancer of the ureters or the urine-collection cavities in the kidney, known as upper tract urothelial carcinoma (UTUC). The study, which compared the characteristics of primary and metastatic tumors, provides new insights into the biology of these aggressive cancers and potential ways to treat them ..read more

More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers has developed an active substance that might in future represent a new treatment option. This substance, known as KMI169, targets an enzyme that plays an important role in the development of prostate cancer ..read more

For 40 years, chemotherapy has been the standard treatment for bladder cancer patients who can tolerate this medicine. However, the results were limited, and lasting results were rare. In recent years, two groundbreaking phase-3 clinical studies have focused on a new form of treatment to improve this. They investigated the effects of combining immunotherapy and chemotherapy ..read more

A high expression of the enzyme beta1,4-galactosyltransferase-3, or B4GALT3 is associated with noticeably shortened survival rates in several types of immunotherapy cancersdeficiency in mice TIME inhibits tumor growth. The study shows that a significant reduction of glycosylation -- a type of protein modification -- on T cell surfaces correlates with increases in CD8+ immune cells infiltrating tumors. Weakly immunogenic and strongly immunogenic tumor cells were subcutaneously transplanted  into B4GALT3 knockout and wild-type mice, to examine for tumor cell growth. Only the knock ..read more

Investigators have developed a new approach for treating invasive bladder cancer without the need for surgical removal of the bladder. Removing the bladder is currently a standard approach when cancer has invaded the muscle layer of the bladder ..read more

Prostate cancer is a leading cause of death among American men, and it's resistant to one of the most powerful chemotherapy medications -- cisplatin. Now, researchers have developed the first therapy of its kind that disrupts prostate cancer cells' metabolism and releases cisplatin into the weakened cells, causing them to die. In mouse models, an orally administered version shrunk tumors substantially ..read more

As men age, some of their cells lose the very thing that makes them biological males -- the Y chromosome -- and this loss hampers the body's ability to fight cancer, according to new research. The study found that loss of the Y chromosome helps cancer cells evade the body's immune system. This common impact of the aging process in men results in aggressive bladder cancer, but somehow also renders the disease more vulnerable -- and responsive -- to a standard treatment called immune checkpoint inhibitors ..read more

Researchers have discovered that colon cancers are often resistant to existing drug treatments because they are composed of two different cell types that can replace each other when one cell type is killed. The study suggests that combination therapies targeting both cell types at once may be more effective at treating colorectal cancer, the third highest cause of cancer-related death in the United States ..read more

Researchers report a study has demonstrated that patients with advanced bladder cancers whose tumors have a mutated FGFR3 gene respond to immunotherapy in a manner that is similar to patients without that mutation. This discovery runs counter to previous research that suggested FGFR3-mutated bladder cancers should not be treated with immunotherapy ..read more